Literature DB >> 11560563

Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark.

S Riahi1, K Fonager, E Toft, L Hvilsted-Rasmussen, J Bendsen, S Paaske Johnsen, H T Sørensen.   

Abstract

AIMS: To examine a) the use of lipid-lowering drugs in North Jutland County in Denmark from 1991 to 1998 and b) the pattern of usage according to sex and age. METHODS AND
RESULTS: We used the Pharmaco-Epidemiological Prescription Database in the county to identify all reimbursed prescriptions for lipid-lowering therapy from 1991 to 1998. One-year incidence rates (IR) and prevalence (P) of the use of lipid-lowering drugs were calculated. Both IR and P of patients in lipid-lowering therapy were stable until 1994, with the IR below 100 per 100 000 for both sexes. The IR then increased from 59.9 to 236.5 per 100 000 person-years in 1998 for women, and from 88.6 to 322.8 per 100 000 person-years for men. The utilization patterns were identical between the sexes. Thus, in both women and men the highest prevalence and incidence rates of lipid-lowering drug therapy were seen in the 60-69-year-olds. Furthermore, the marked increase in both prevalence and incidence of persons on lipid-lowering drug therapy between 1994 and 1998 was the result of an increased number of prescriptions in the 50-59, 60-69 and 70 + years olds, in both women and men. There was a remarkable 4-5 fold increase in the numbers of new patients who received statins during the same period.
CONCLUSIONS: The overall use of lipid-lowering drugs has increased markedly over the last few years in Northern Jutland, Denmark. The increase began following publication of the first major trial documenting the benefit of therapy with statins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560563      PMCID: PMC2014543          DOI: 10.1046/j.0306-5251.2001.01439.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Use of cholesterol-lowering medications in the United States from 1991 to 1997.

Authors:  D Siegel; J Lopez; J Meier
Journal:  Am J Med       Date:  2000-04-15       Impact factor: 4.965

Review 2.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

3.  Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden.

Authors:  N Magrini; T Einarson; A Vaccheri; P McManus; N Montanaro; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  The Pharmacoepidemiologic Prescription Database of North Jutland - a valid tool in pharmacoepidemiological research.

Authors:  G L Nielsen; H T Sørensen; W Zhou; F H Steffensen; J Olsen
Journal:  Int J Risk Saf Med       Date:  1997

5.  Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

Authors:  M Miller; R Byington; D Hunninghake; B Pitt; C D Furberg
Journal:  Arch Intern Med       Date:  2000-02-14

6.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.

Authors:  P McBride; H G Schrott; M B Plane; G Underbakke; R L Brown
Journal:  Arch Intern Med       Date:  1998-06-08

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.

Authors:  M R Law; N J Wald; T Wu; A Hackshaw; A Bailey
Journal:  BMJ       Date:  1994-02-05

9.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

Authors:  S J Lewis; F M Sacks; J S Mitchell; C East; S Glasser; S Kell; R Letterer; M Limacher; L A Moye; J L Rouleau; M A Pfeffer; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  13 in total

1.  Survival trends among Danish patients undergoing coronary angiography for known or suspected ischaemic heart disease: a population based follow up study, 1992-2000.

Authors:  S P Johnsen; J Videbaek; L Pedersen; R Steffensen; R Videbaek; T Niemann; T T Nielsen; H T Sørensen
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

2.  Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland.

Authors:  Päivi Ruokoniemi; Arja Helin-Salmivaara; Timo Klaukka; Pertti J Neuvonen; Risto Huupponen
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

3.  Statin use after acute myocardial infarction: a nationwide study in Denmark.

Authors:  Jeppe N Rasmussen; Gunnar H Gislason; Steen Z Abildstrom; Søren Rasmussen; Ida Gustafsson; Pernille Buch; Jens Friberg; Lars Køber; Christian Torp-Pedersen; Mette Madsen; Steen Stender
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

4.  Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study.

Authors:  Reimar W Thomsen; Søren P Johnsen; Anne V Olesen; Jens T Mortensen; Henrik Bøggild; Jørn Olsen; Henrik T Sørensen
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

5.  Hip fracture risk in statin users--a population-based Danish case-control study.

Authors:  Lars Rejnmark; Mette Lena Olsen; Søren Paaske Johnsen; Peter Vestergaard; Henrik Toft Sørensen; Leif Mosekilde
Journal:  Osteoporos Int       Date:  2004-02-17       Impact factor: 4.507

6.  Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.

Authors:  Wei-Hsuan Lo-Ciganic; Robert M Boudreau; Shelly L Gray; Janice C Zgibor; Julie M Donohue; Subashan Perera; Anne B Newman; Eleanor M Simonsick; Douglas C Bauer; Suzanne Satterfield; Joseph T Hanlon
Journal:  Ann Pharmacother       Date:  2013-06-18       Impact factor: 3.154

7.  Statin use and risk for ovarian cancer: a Danish nationwide case-control study.

Authors:  L Baandrup; C Dehlendorff; S Friis; J H Olsen; S K Kjær
Journal:  Br J Cancer       Date:  2014-11-13       Impact factor: 7.640

8.  Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions.

Authors:  Sigrun Alba Johannesdottir; Erzsébet Horváth-Puhó; Vera Ehrenstein; Morten Schmidt; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2012-11-12       Impact factor: 4.790

9.  Use of statins and risk of glioma: a nationwide case-control study in Denmark.

Authors:  D Gaist; L Andersen; J Hallas; H Toft Sørensen; H D Schrøder; S Friis
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

10.  Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.

Authors:  Ingeborg Hartz; Solveig Sakshaug; Kari Furu; Anders Engeland; Anne Elise Eggen; Inger Njølstad; Svetlana Skurtveit
Journal:  BMC Clin Pharmacol       Date:  2007-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.